San Jose, California (PRWEB) November 16, 2011

Follow us on LinkedIn – Automated and rapid microbiological tests have emerged into a core subdivision of applied microbiology. These tests have been largely gaining importance as a major area of research and application, for examining various kinds of microorganisms that are root cause of several diseases. With humans and bacteria locked in a perennial biological warfare, there exists a perpetual need for new and advanced rapid microbial testing methods and instruments. In addition, with fresh outbreaks of new diseases caused by ever changing and adapting mutating variants of bacteria, identifying pathogens in food, water, environment, and in the human body continues to gain importance. The ability to positively impact public health lies in quick, rapid and accurate identification of an infection and its causative bacterium. Learning to track, find, prevent and destroy these pathogens is a constant challenge confronting the medical community, which in turn ensures secure future for the automated and rapid microbiological tests market.

Advancements in technology are leading to sweeping changes in the market for automated and rapid microbiological tests. Time constraints plaguing traditional testing methods are driving laboratories to opt for automated and rapid microbiological tests. Rapid tests allow for quantitative detection of pathogens in as short a time as 1-2 days, in contrast to conventional testing which takes 5-10 days. A vast majority of first-generation rapid tests are based on technologies such as immunoassays, chromatography and polymerase chain reactions, while second-generation rapid tests are engineered on advanced concepts of biotechnology and molecular diagnostics. The sheer number of rapid tests and their various technologies available in the market unnerves prospective buyers thereby making an appropriate purchase decision a hard task. Intimidated by the numerous high-flown technology related issues, buyers generally find themselves caught in a quagmire of environment-product-need fulfillment pros and cons that ultimately shape the systems ability to truly meet specific end-user requirements and needs.

As stated by the new market research report on Automated and Rapid Microbiological Tests, the US continues to remain the largest regional market. Rapid microbiological tests market in the US is replete with strong market-focused players, with a broad portfolio of tests along with highly specialized offerings. Market saturation coupled with moderate price sensitivity is spawning an era of vertical and horizontal integration across the market, enabling companies to optimally target customers with broad-based, cost-efficient test services, given the low level of technology development. Advancements in molecular diagnosis such as the genetic probe tests hold the potential to cannibalize the market for traditional rapid microbiology tests.

Europe is expected to grow at a CAGR of about 5.6% over the analysis period. Rest of World market, comprising emerging economies of Asia Pacific and Latin America, offers significant growth opportunities in the automated microbiological test systems segment. With numerous laboratories continuing to grow in these regions, upgradation to automated instrumentation systems is expected to rank as the top priority in coming years. The market for Automated Identification and Susceptibility Systems is the largest end-use segment, while GC/Chlamydia Rapid Tests represents the fastest growing end-use segment with a CAGR of 5.3% over the review period.

Major players in the marketplace include Abbott Laboratories, Alere Inc., Becton Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc., Cellabs Pty Ltd, Celsis International Plc, Coris BioConcept, F. Hoffmann-La Roche Ltd., Gen-Probe Inc., Sekisui Diagnostics LLC, MedMira Inc., Meridian Biosciences Inc., Orasure Technologies Inc., Orion Diagnostica Oy, Quidel Corp., Siemens Healthcare Diagnostics Inc., and Thermo Fisher Scientific Inc.

The research report titled “Automated and Rapid Microbiological Tests: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, issues, strategic industry activities, and profiles of major companies worldwide. The report provides market estimates and projections (US$ Million) for end-use segments Clinical Applications (Automated Identification & Susceptibility Systems; Automated Blood Culture Systems; Automated Tuberculosis Systems; Streptococcal Infection Rapid Tests; GC/Chlamydia Rapid Tests; and Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications, across geographic markets such as the US, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), and Rest of World.

For more details about this comprehensive market research report, please visit http://www.strategyr.com/Automated_And_Rapid_Microbiological_Tests_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###





Tagged with: